Joint Counts to Assess Rheumatoid Arthritis for Clinical Research and Usual Clinical Care: Advantages and Limitations

Rheumatic Disease Clinics of North America

Volumn 35, Issue 4, 2009, Pages 713-722

  Sokka, Tuulikki ^a   Pincus, Theodore ^b  

^a JYVÄSKYLÄ CENTRAL HOSPITAL   (Finland)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Joint count; Joint examination; Quantitative assessment; Self report questionnaire

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; LEFLUNOMIDE; METHOTREXATE; PLACEBO;

CLINICAL RESEARCH; CLINICAL TRIAL; DISEASE ACTIVITY; ECHOGRAPHY; ERYTHROCYTE SEDIMENTATION RATE; FUNCTIONAL DISEASE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; INTERRATER RELIABILITY; JOINT DESTRUCTION; JOINT EXAMINATION; JOINT SWELLING; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT CARE; PLACEBO EFFECT; PRIORITY JOURNAL; QUESTIONNAIRE; REVIEW; RHEUMATOID ARTHRITIS; SELF REPORT; SYNOVITIS; TEST RETEST RELIABILITY; WORK DISABILITY;

ARTHRITIS, RHEUMATOID; DISABILITY EVALUATION; HUMANS; JOINTS; PHYSICAL EXAMINATION; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 70949087505     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rdc.2009.10.004     Document Type: Review

References (62)

1. Pincus T. The DAS is the most specific measure, but a patient questionnaire is the most informative measure to assess rheumatoid arthritis. J Rheumatol 33 (2006) 834-837
2. Cooperating Clinics Committee of the American Rheumatism Association. A seven-day variability study of 499 patients with peripheral rheumatoid arthritis. Arthritis Rheum 8 (1965) 302-335
3. Ritchie D.M., Boyle J.A., McInnes J.M., et al. Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. New Series. Q J Med 37 (1968) 393-406
4. American Rheumatism Association. Dictionary of the rheumatic diseases. Signs and symptoms vol. I (1982), Contact Associates International, New York
5. Decker J.L. American Rheumatism Association nomenclature and classification of arthritis and rheumatism. Arthritis Rheum 26 (1983) 1029-1032
6. Bombardier C., Tugwell P., Sinclair A., et al. Preference for endpoint measures in clinical trials: results of structured workshops. J Rheumatol 9 (1982) 798-801
7. Wolfe F., Pincus T., Thompson A.K., et al. The assessment of rheumatoid arthritis and the acceptability of self-report questionnaires in clinical practice. Arthritis Care Res 49 1 (2003) 59-63
8. Boers M., Tugwell P., Felson D.T., et al. World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. J Rheumatol 21 Suppl 41 (1994) 86-89
9. Felson D.T., Anderson J.J., Boers M., et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 36 (1993) 729-740
10. American College of Rheumatology Committee to Reevaluate Improvement Criteria. A proposed revision to the ACR20: the hybrid measure of American College of Rheumatology response. Arthritis Rheum 57 2 (2007) 193-202
11. Goldsmith C.H., Smythe H.A., and Helewa A. Interpretation and power of pooled index. J Rheumatol 20 (1993) 575-578
12. van der Heijde D.M., van't Hof M.A., van Riel P.L., et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 49 (1990) 916-920
13. van der Heijde D.M., van't Hof M., van Riel P.L., and van de Putte L.B. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 20 (1993) 579-581
14. Aletaha D., and Smolen J. The simplified disease activity index (SDAI) and the clinical disease activity index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 23 (2005) S100-S108
15. Lansbury J., Baier H.N., and McCracken S. Statistical study of variation in systemic and articular indexes. Arthritis Rheum 5 (1962) 445-456
16. Eberl D.R., Fasching V., Rahlfs V., et al. Repeatability and objectivity of various measurements in rheumatoid arthritis: a comparative study. Arthritis Rheum 19 (1976) 1278-1286
17. Hanson M.T., Keiding S., Lauritzen S.L., et al. Clinical assessment of disease activity in rheumatoid arthritis. Scand J Rheumatol 8 (1979) 101-105
18. Hart L.E., Tugwell P., Buchanan W.W., et al. Grading of tenderness as a source of interrater error in the Ritchie articular index. J Rheumatol 12 (1985) 716-717
19. Thompson P.W., and Kirwan J.R. Observer variation and the Ritchie articular index. J Rheumatol 13 (1986) 836-837
20. Lewis P.A., O'Sullivan M.M., Rumfeld W.R., et al. Significant changes in Ritchie scores. Br J Rheumatol 27 (1988) 32-36
21. Klinkhoff A.V., Bellamy N., Bombardier C., et al. An experiment in reducing interobserver variability of the examination for joint tenderness. J Rheumatol 15 (1988) 492-494
22. Thompson P.W., Kirwan J.R., and Currey H.L.F. A comparison of the ability of 28 articular indices to detect an induced flare of joint inflammation in rheumatoid arthritis. Br J Rheumatol 27 (1988) 375-380
23. Fuchs H.A., Brooks R.H., Callahan L.F., et al. A simplified twenty-eight joint quantitative articular index in rheumatoid arthritis. Arthritis Rheum 32 (1989) 531-537
24. Thompson P.W., Hart L.E., Goldsmith C.H., et al. Comparison of four articular indices for use in clinical trials in rheumatoid arthritis: patient, order and observer variation. J Rheumatol 18 (1991) 661-665
25. Bellamy N., Anastassiades T.P., Buchanan W.W., et al. Rheumatoid arthritis antirheumatic drug trials. 1. Effects of standardization procedures on observer dependent outcome measures. J Rheumatol 18 (1991) 1893-1900
26. Scott D.L., Choy E.H.S., Greeves A., et al. Standardising joint assessment in rheumatoid arthritis. Clin Rheumatol 15 (1996) 579-582
27. Lassere M.N.D., van der Heijde D., Johnson K.R., et al. Reliability of measures of disease activity and disease damage in rheumatoid arthritis: implications for smallest detectable difference, minimal clinically important difference, and analysis of treatment effects in randomized controlled trials. J Rheumatol 28 4 (2001) 892-903
28. Sokka T., and Pincus T. Quantitative joint assessment in rheumatoid arthritis. Clin Exp Rheumatol 23 (2005) S58-S62
29. Pincus T. Limitations of a quantitative swollen and tender joint count to assess and monitor patients with rheumatoid arthritis. Bull NYU Hosp Jt Dis 66 3 (2008) 216-223
30. Tugwell P., Wells G., Strand V., et al. Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. Arthritis Rheum 43 3 (2000) 506-514
31. Strand V., Cohen S., Crawford B., et al. Patient-reported outcomes better discriminate active treatment from placebo in randomized controlled trials in rheumatoid arthritis. Rheumatology 43 (2004) 640-647
32. Pincus T., Strand V., Koch G., et al. An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from placebo as effectively as the American College of Rheumatology 20% response criteria (ACR20) or the disease activity score (DAS) in a rheumatoid arthritis clinical trial. Arthritis Rheum 48 3 (2003) 625-630
33. Pincus T., Amara I., and Koch G.G. Continuous indices of Core Data Set measures in rheumatoid arthritis clinical trials: lower responses to placebo than seen with categorical responses with the American College of Rheumatology 20% criteria. Arthritis Rheum 52 (2005) 1031-1036
34. Pincus T., Chung C., Segurado O.G., et al. An index of patient self-reported outcomes (PRO Index) discriminates effectively between active and control treatment in 4 clinical trials of adalimumab in rheumatoid arthritis. J Rheumatol 33 (2006) 2146-2152
35. Pincus T., Bergman M.J., Yazici Y., et al. An index of only patient-reported outcome measures, routine assessment of patient index data 3 (RAPID3), in two abatacept clinical trials: similar results to disease activity score (DAS28) and other RAPID indices that include physician-reported measures. Rheumatology (Oxford) 47 3 (2008) 345-349
36. Pincus T., Amara I., Segurado O.G., et al. Relative efficiencies of physician/assessor global estimates and patient questionnaire measures are similar to or greater than joint counts to distinguish adalimumab from control treatments in rheumatoid arthritis clinical trials. J Rheumatol 35 2 (2008) 201-205
37. Gotzsche P.C. Sensitivity of effect variables in rheumatoid arthritis: a meta-analysis of 130 placebo controlled NSAID trials. J Clin Epidemiol 43 (1990) 1313-1318
38. Bombardier C., and Raboud J. A comparison of health-related quality-of-life measures for rheumatoid arthritis research. The Auranofin Cooperating Group. Control Clin Trials 12 (1991) 243S-256S
39. Cohen S.B., Strand V., Aguilar D., et al. Patient- versus physician-reported outcomes in rheumatoid arthritis patients treated with recombinant interleukin-1 receptor antagonist (anakinra) therapy. Rheumatology 43 6 (2004) 704-711
40. Anderson J.J., Felson D.T., Meenan R.F., et al. Which traditional measures should be used in rheumatoid arthritis clinical trials?. Arthritis Rheum 32 (1989) 1093-1099
41. Callahan L.F., Pincus T., Huston III J.W., et al. Measures of activity and damage in rheumatoid arthritis: depiction of changes and prediction of mortality over five years. Arthritis Care Res 10 (1997) 381-394
42. Scott D.L., Grindulis K.A., Struthers G.R., et al. Progression of radiological changes in rheumatoid arthritis. Ann Rheum Dis 43 (1984) 8-17
43. Pincus T., Callahan L.F., Sale W.G., et al. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum 27 (1984) 864-872
44. Hawley D.J., and Wolfe F. Sensitivity to change of the Health Assessment Questionnaire (HAQ) and other clinical and health status measures in rheumatoid arthritis: results of short term clinical trials and observational studies versus long term observational studies. Arthritis Care Res 5 (1992) 130-136
45. Sharp J.T., Wolfe F., Mitchell D.M., et al. The progression of erosion and joint space narrowing scores in rheumatoid arthritis during the first twenty-five years of disease. Arthritis Rheum 34 (1991) 660-668
46. Egsmose C., Lund B., Borg G., et al. Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year followup of a prospective double blind placebo controlled study. J Rheumatol 22 (1995) 2208-2213
47. Fex E., Jonsson K., Johnson U., et al. Development of radiographic damage during the first 5-6 yr of rheumatoid arthritis. A prospective follow-up study of a Swedish cohort. Br J Rheumatol 35 (1996) 1106-1115
48. Mulherin D., Fitzgerald O., and Bresnihan B. Clinical improvement and radiological deterioration in rheumatoid arthritis: evidence that pathogenesis of synovial inflammation and articular erosion may differ. Br J Rheumatol 35 (1996) 1263-1268
49. Leirisalo-Repo M., Paimela L., Peltomaa R., et al. Functional and radiological outcome in patients with early RA-a longitudinal observational study. [abstract]. Arthritis Rheum 42 (1999) S130
50. Graudal N., Tarp U., Jurik A.G., et al. Inflammatory patterns in rheumatoid arthritis estimated by the number of swollen and tender joints, the erythrocyte sedimentation rate, and hemoglobin: longterm course and association to radiographic progression. J Rheumatol 27 (2000) 47-57
51. Welsing P.M.J., van Gestel A.M., Swinkels H.L., et al. The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum 44 9 (2001) 2009-2017
52. Puolakka K., Kautiainen H., Möttönen T., et al. Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial. Arthritis Rheum 52 1 (2005) 36-41
53. Puolakka K., Kautiainen H., Mottonen T., et al. Predictors of productivity loss in early rheumatoid arthritis: a 5 year follow up study. Ann Rheum Dis 64 (2005) 130-133
54. Pincus T. The case for early intervention in rheumatoid arthritis. J Autoimmun 5 Suppl A (1992) 209-226
55. Pincus T., and Callahan L.F. The 'side effects' of rheumatoid arthritis: Joint destruction, disability and early mortality. Br J Rheumatol 32 Suppl 1 (1993) 28-37
56. Emery P., and Salmon M. Early rheumatoid arthritis: time to aim for remission?. Ann Rheum Dis 54 (1995) 944-947
57. Weinblatt M.E. Rheumatoid arthritis: treat now, not later!. [editorial]. Ann Intern Med 124 (1996) 773-774
58. Pincus T., Gibofsky A., and Weinblatt M.E. Urgent care and tight control of rheumatoid arthritis as in diabetes and hypertension: better treatments but a shortage of rheumatologists. Arthritis Rheum 46 4 (2002) 851-854
59. Wakefield R.J., Green M.J., Marzo-Ortega H., et al. Should oligoarthritis be reclassified? Ultrasound reveals a high prevalence of subclinical disease. Ann Rheum Dis 63 (2004) 382-385
60. Pincus T., and Segurado O.G. Most visits of most patients with rheumatoid arthritis to most rheumatologists do not include a formal quantitative joint count. Ann Rheum Dis 65 (2006) 820-822
61. Karim Z., Wakefield R.J., Quinn M., et al. Validation and reproducibility of ultrasonography in the detection of synovitis in the knee: a comparison with arthroscopy and clinical examination. Arthritis Rheum 50 (2004) 387-394
62. Kane D., Balint P.V., and Sturrock R.D. Ultrasonography is superior to clinical examination in the detection and localization of knee joint effusion in rheumatoid arthritis. J Rheumatol 30 (2003) 966-971